(Total Views: 790)
Posted On: 08/27/2021 5:27:13 PM
Post# of 158162
Re: Genentech pulls mTNBC drug. The following comment was approved by Medpage's well-schooled moderators within an hour:
"Better mTNBC biologics are in testing. Did Genentech perhaps see the 8/25 release regarding leronlimab results in mTNBC patients?
* 30 patients, combined Phase 1b/2 and compassionate use
* 22 of those showed decreased circulating tumor cells (nice new blood test)
* That group showed " (a) 400%-660% increase in mPFS (modified Progression Free Survival) ... and (b) a 570%-980% increase in mOS (modified Overall Survival) ...."
This CCR5 antagonist is fast-tracked for two indications. Its other oncology trial is a Phase 2 in a basket of 22 solid tumors. Excellent safety record in over 1,000 (mostly HIV) patients."
"Better mTNBC biologics are in testing. Did Genentech perhaps see the 8/25 release regarding leronlimab results in mTNBC patients?
* 30 patients, combined Phase 1b/2 and compassionate use
* 22 of those showed decreased circulating tumor cells (nice new blood test)
* That group showed " (a) 400%-660% increase in mPFS (modified Progression Free Survival) ... and (b) a 570%-980% increase in mOS (modified Overall Survival) ...."
This CCR5 antagonist is fast-tracked for two indications. Its other oncology trial is a Phase 2 in a basket of 22 solid tumors. Excellent safety record in over 1,000 (mostly HIV) patients."
(19)
(0)
